You just read:

I-Mab Biopharma Announces the Achievement of First Patient Dosing in Phase 1b/2a China Trial of TJ107 for Cancer and Chemotherapy-induced Lymphopenia

News provided by

I-Mab Biopharma

Mar 05, 2019, 02:30 ET